INVESTIGATIONS INTO HYPERLIPIDEMIA AND ITS POSSIBLE ...

More documents

Recommendations

Info

197 216. Steiner JM. Exocrine pancreas. In: Steiner JM. ed. Small animal gastroenterology. Hannover: Schlütersche; 2008:283-306. 217. Asfar P, Hauser B, Radermacher P, et al. Catecholamines and vasopressin during critical illness. Crit Care Clin 2006;22:131-149. 218. Muir WW. Pain and stress. In: Gaynor JS, Muir WW. eds. Handbook of veterinary pain management. St. Louis: Mosby Elsevier; 2009:42-59. 219. Benchaoui HA, Cox SR, Schneider RP, et al. The pharmacokinetics of maropitant, a novel neurokinin type-1 receptor antagonist, in dogs. J Vet Pharmacol Ther 2007;30:336-344. 220. Puente-Redondo VA, Siedek EM, Benchaoui HA, et al. The anti-emetic efficacy of maropitant (Cerenia) in the treatment of ongoing emesis caused by a wide range of underlying clinical aetiologies in canine patients in Europe. J Small Anim Pract 2007;48:93-98. 221. Sedlacek HS, Ramsey DS, Boucher JF, et al. Comparative efficacy of maropitant and selected drugs in preventing emesis induced by centrally or peripherally acting emetogens in dogs. J Vet Pharmacol Ther 2008;31:533-537. 222. Hart PA, Bechtold ML, Marshall JB, et al. Prophylactic antibiotics in necrotizing pancreatitis: a meta-analysis. South Med J 2008;101:1126-1131. 223. Jafri NS, Mahid SS, Idstein SR, et al. Antibiotic prophylaxis is not protective in severe acute pancreatitis: a systematic review and meta-analysis. Am J Surg 2009;197:806-813.
198 224. Koch K, Drewelow B, Liebe S, et al. Penetration of antibiotics into the pancreas. Chirurg 1991;62:317-322. 225. Trudel JL, Wittnich C, Brown RA. Antibiotics bioavailability in acute experimental pancreatitis. J Am Coll Surg 1994;178:475-479. 226. Platell C, Cooper D, Hall JC. A meta-analysis of peritoneal lavage for acute pancreatitis. J Gastroenterol Hepatol 2001;16:689-693. 227. Bassi C, Briani G, Vesentini S, et al. Continuous peritoneal dialysis in acute experimental pancreatitis in dogs. Effect of aprotinin in the dialysate medium. Int J Pancreatol 1989;5:69-75. 228. Salisbury SK, Lantz GC, Nelson RW, et al. Pancreatic abscess in dogs: six cases (1978-1986). J Am Vet Med Assoc 1988;193:1104-1108. 229. Edwards DF, Bauer MS, Walker MA, et al. Pancreatic masses in seven dogs following acute pancreatitis. J Am Anim Hosp Assoc 1990;26:189-198. 230. Stimson EL, Espada Y, Moon M, et al. Pancreatic abscess in nine dogs. J Vet Intern Med 1998;9:202. 231. Johnson MD, Mann FA. Treatment for pancreatic abscesses via omentalization with abdominal closure versus open peritoneal drainage in dogs: 15 cases (1994-2004). J Am Vet Med Assoc 2006;228:397-402. 232. Anderson JR, Cornell KK, Parnell NK, et al. Pancreatic abscess in 36 dogs: a retrospective analysis of prognostic indicators. J Am Anim Hosp Assoc 2008;44:171- 179.
Page 1 and 2:
INVESTIGATIONS INTO HYPERLIPIDEMIA
Page 3 and 4:
INVESTIGATIONS INTO HYPERLIPIDEMIA
Page 5 and 6:
iv was found to be useful for the s
Page 7 and 8:
vi ACKNOWLEDGEMENTS I would like to
Page 9 and 10:
viii TABLE OF CONTENTS Page ABSTRAC
Page 11 and 12:
x LIST OF FIGURES FIGURE Page 1 Cor
Page 13 and 14:
xii FIGURE Page 20 1-dimensional sl
Page 15 and 16:
2 the results of these initial stud
Page 17 and 18:
4 and HDL 1 concentrations and a de
Page 19 and 20:
6 and, in smaller concentrations, L
Page 21 and 22:
8 HDL molecules can be further subd
Page 23 and 24:
10 reach the vasculature, they acqu
Page 25 and 26:
12 Endocrine disease Most commonly,
Page 27 and 28:
14 with varying frequencies in dogs
Page 29 and 30:
16 hypercholesterolemia was found o
Page 31 and 32:
18 Primary hyperlipidemia with hype
Page 33 and 34:
20 Atherosclerosis Although dogs ap
Page 35 and 36:
22 Dietary management Typically, th
Page 37 and 38:
24 therapy when the latter fails to
Page 39 and 40:
26 followed from the 1970s until to
Page 41 and 42:
28 this theory, zymogen granules th
Page 43 and 44:
30 be quite different, especially i
Page 45 and 46:
32 Drugs As in humans, drug-induced
Page 47 and 48:
34 Signalment Dogs of any age, bree
Page 49 and 50:
36 erroneously direct the clinician
Page 51 and 52:
38 of changes over time in serum Sp
Page 53 and 54:
40 they have been shown to have a l
Page 55 and 56:
42 revealed either a normal pancrea
Page 57 and 58:
44 At present, a definitive diagnos
Page 59 and 60:
46 factors should always be investi
Page 61 and 62:
48 associated pancreatitis is much
Page 63 and 64:
50 clear whether hyperlipidemia was
Page 65 and 66:
52 hepatobiliary disease in both Mi
Page 67 and 68:
54 the reference range, while Group
Page 69 and 70:
56 ROC analysis and calculation of
Page 71 and 72:
58 Figure 3. Serum cPLI concentrati
Page 73 and 74:
60 There was no significant differe
Page 75 and 76:
62 severe (typically ≥1,000 mg/dl
Page 77 and 78:
64 gastrointestinal signs or suspec
Page 79 and 80:
66 CHAPTER III SERUM TRIGLYCERIDE C
Page 81 and 82:
68 logical assumption that a defect
Page 83 and 84:
70 pancreatitis. For the same reaso
Page 85 and 86:
72 Spec cPL concentrations were mea
Page 87 and 88:
74 were significantly more likely t
Page 89 and 90:
76 Figure 5. Comparison of serum tr
Page 91 and 92:
78 Figure 7. Comparison of serum tr
Page 93:
80 pancreatitis as it cannot be pre
Page 96 and 97:
83 Although serum cholesterol conce
Page 98 and 99:
85 Footnotes a Spec cPL ® , IDEXX
Page 100 and 101:
87 several subfractions, with diffe
Page 102 and 103:
89 Miniature Schnauzers (Group 2) T
Page 104 and 105:
91 Assays Serum triglyceride (refer
Page 106 and 107:
93 Figure 8. Custom-built fluoresce
Page 108 and 109:
95 range HDL 1 has not been accurat
Page 110 and 111:
97 mg/dL) were significantly higher
Page 112 and 113:
99 Figure 10: Serum cholesterol con
Page 114 and 115:
101 (Eigenvalues=0.5455; P=0.00017;
Page 116 and 117:
103 Figure 12: Representative lipop
Page 118 and 119:
105 Figures 14A and 14B: Representa
Page 120 and 121:
107 Specifically, 97% of non-hypert
Page 122 and 123:
109 The fraction of TRLs was a sign
Page 124 and 125:
111 Schnauzers without hyperlipidem
Page 126 and 127:
113 Footnotes a Roche/Hitachi MODUL
Page 128 and 129:
115 The biochemical, metabolic, and
Page 130 and 131:
117 Study design Each one of the do
Page 132 and 133:
119 Questionnaires and consent form
Page 134 and 135:
121 a target intensity of 30%, and
Page 136 and 137:
123 might affect lipid metabolism (
Page 138 and 139:
125 Figure 16. Serum triglyceride c
Page 140 and 141:
127 Figure 18. Serum Spec cPL conce
Page 142 and 143:
129 Figure 19. 1-dimensional sliced
Page 144 and 145:
131 Dogs that did not respond to th
Page 146 and 147:
133 Hypertriglyceridemia has been l
Page 148 and 149:
135 degrees. One possible explanati
Page 150 and 151:
137 Footnotes a Royal Canin Gastroi
Page 152 and 153:
139 concentrations and lipoprotein
Page 154 and 155:
141 inclusion criteria for the stud
Page 156 and 157:
143 light source j , located in a d
Page 159 and 160: 146 Serum triglyceride and choleste
Page 161 and 162: 148 Figure 22. Serum triglyceride c
Page 163 and 164: 150 Figure 24. 1-dimensional sliced
Page 165 and 166: 152 Discussion The purpose of the p
Page 167 and 168: 154 fraction of these dogs (about 3
Page 169 and 170: 156 of lipoproteins might also have
Page 171 and 172: 158 Footnotes a Roche/Hitachi MODUL
Page 173 and 174: 160 the etiology of pancreatitis, b
Page 175 and 176: 162 times (P=0.0343) for a serum cP
Page 177 and 178: 164 peaks than dogs of other breeds
Page 179 and 180: 166 19.3; 95% CI, 2.0-184.0; P=0.00
Page 181 and 182: 168 4) Specific lipoprotein classes
Page 183 and 184: 170 REFERENCES 1949;8:96-97. 1. Lew
Page 185 and 186: 172 17. Whitney MS, Boon GD, Rebar
Page 187 and 188: 174 33. Ford RB. Clinical managemen
Page 189 and 190: 176 50. Nelson RW, Turnwald GH, Wil
Page 191 and 192: 178 66. Williams DA, Steiner JM. Ca
Page 193 and 194: 180 82. Yilmaz Z, Senturk S. Charac
Page 195 and 196: 182 97. Fojo SS, Stalenhoef AF, Mar
Page 197 and 198: 184 111. Lam CW, Yuen YP, Cheng WF,
Page 199 and 200: 186 127. Crispin SM. Ocular manifes
Page 201 and 202: 188 144. Lindsay S, Entenmann C, Ch
Page 203 and 204: 190 161. Steiner JM. Canine pancrea
Page 205 and 206: 192 176. Steiner JM, Teague SR, Wil
Page 207 and 208: 194 191. Steiner JM. Diagnosis of p
Page 209: 196 208. Talukdar R, Vege S. Recent
Page 213 and 214: 200 241. Petrov MS, van Santvoort H
Page 215 and 216: 202 258. Ewald N, Hardt PD, Kloer H
Page 217 and 218: 204 274. Otvos JD, Jeyarajah EJ, Be
Page 219 and 220: 206 289. Carpentier YA, Scruel O. C
show all

INVESTIGATIONS INTO HYPERLIPIDEMIA AND ITS POSSIBLE ...

Create successful ePaper yourself

Delete template?

Save as template?